A
Alcista
Alcista · 25%CLDX
$42.51
Precio del escenario
$27.835
-0.409 (-1.47%)Al cierre
Loading chart…
- Máximo
- 28.730
- Apertura
- 28.490
- Precio medio ponderado por volumen
- 28.08
- Volumen
- 1.04M
- Capitalización
- 2.48B
- Mínimo
- 27.680
- Importe
- 29.33M
- EV/EBITDA, TTM
- -0.06
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Análisis de IA of Celldex Therapeutics Inc (CLDX)
ComprarCelldex Therapeutics Inc is a good buy right now, trading at $29.89 with a strong upside potential. Analysts have set a price target of $64, indicating a potential upside of 114% from the current price. Additionally, the company has reported a gross margin of 100%, showcasing its strong profitability potential despite current losses. The main risk is its negative earnings per share (EPS) of -0.94, which reflects ongoing financial challenges.
Recomendaciones de analistas (7)
+97.59% de potencial alcista
Comprar
4 Comprar
3 Mantener
0 Vender
Actual: 27.84
Mínimo
24.00
Promedio
55.00
Máximo
90.00
H.C. Wainwright
Comprar
$64
2026-10-02
H.C. Wainwright
2026-10-02
Precio objetivo
$64
Comprar
Leerink
Superar al mercado
$88
2026-09-23
Leerink
2026-09-23
Precio objetivo
$88
Superar al mercado
Morgan Stanley
Sobreponderar
$57
2026-09-23
Morgan Stanley
2026-09-23
Precio objetivo
$57
Sobreponderar
H.C. Wainwright
Comprar
$64
2026-09-22
H.C. Wainwright
2026-09-22
Precio objetivo
$64
Comprar
Morgan Stanley
Sobreponderar
$46
2026-08-07
Morgan Stanley
2026-08-07
Precio objetivo
$46
Sobreponderar
Métricas de valoración
El PER previsto actual de Celldex Therapeutics Inc (CLDX) es 0.00, frente a su media de 5 años de -11.86.
Escenarios de precio de Alphio AI para CLDX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CLDX en cartera
Cronología de eventos
Noticias
7.010-12PRnewswireInvestigation Launched into Celldex Therapeutics by Purcell & Lefkowitz LLP
6.009-22stocktwitsCelldex Price Target Raised to $64 Amid Positive Study Results
9.009-22NASDAQ.COMCelldex Reports Positive Phase 3 Results for Barzolvolimab
9.009-22NASDAQ.COMCelldex Reports Positive Phase 3 Results for Barzolvolimab in Chronic Urticaria
1.009-08Yahoo FinanceCelldex to Participate in Cantor Global Healthcare Conference
Preguntas frecuentes sobre CLDX, respondidas por Alphio AI
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
Celldex Therapeutics Inc is a good buy right now, trading at $29.89 with a strong upside potential. Analysts have set a price target of $64, indicating a potential upside of 114% from the current price. Additionally, the company has reported a gross margin of 100%, showcasing its strong profitability potential despite current losses. The main risk is its negative earnings per share (EPS) of -0.94, which reflects ongoing financial challenges.
7 analysts cover CLDX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 55.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.